The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

The first session from iwNHL focused on advances in the treatment and management of T-cell lymphoma. In this podcast, Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, François Lemonnier, MD, Henri Mondor University Hospital, Créteil, France, and David Sibon, MD, PhD, Henri Mondor University Hospital, Créteil, France, discuss the safety and efficacy of brentuximab vedotin in enteropathy-associated T-cell lymphomas (EATL), epigenetic drugs and TRBC1-directed CAR-T therapy in T-cell lymphoma, and novel developments in the field of cutaneous T-cell lymphoma (CTCL).

The post iwNHL 2022 Session I: advances in the treatment of T-cell lymphoma appeared first on VJHemOnc.